Kaisa Health Group Holdings Limited – Special General Meeting Notice and Key Corporate Actions
Summary of Key Points
- Special General Meeting (SGM) Scheduled: The SGM will be held on Monday, 22 June 2026 at 11:00 a.m., at Conference Room Luxe Lab, 20/F., Office Plus @Sheung Wan, Hong Kong.
- Major Acquisition Proposal: Shareholders are asked to approve the acquisition of the entire issued share capital of Embrace Blossom Limited by Kaisa Health Group Holdings Limited from Profit Vigorous Developments Limited (the Vendor).
- Share Issuance: The Company will issue new shares to the Vendor as consideration for the acquisition:
- If a planned Share Consolidation is effective, 2,491,042 Consideration Shares will be issued at HK\$9.8 per share.
- If the Share Consolidation does not take effect, 124,552,111 Consideration Shares will be issued at HK\$0.196 per share.
- Share Consolidation: The Company proposes to consolidate every fifty (50) issued and unissued ordinary shares with a par value of HK\$0.00125 each into one (1) ordinary share with a par value of HK\$0.0625 each. This will significantly reduce the number of shares in issue and may impact market liquidity and share price.
- Director Authorization: Directors will be given mandate to execute all necessary documents and actions to complete the acquisition, share issuance, and share consolidation.
- Shareholder Voting: All resolutions will be decided by poll; shareholders can appoint proxies to attend and vote.
- Closure of Register of Members: The register will be closed from 16 June to 22 June 2026. Share transfers must be lodged by 15 June 2026 to qualify for voting and attendance.
- Weather Contingency: Arrangements for postponement in case of severe weather signals in Hong Kong are specified.
Potential Price-Sensitive Information for Investors
- Acquisition of Embrace Blossom Limited: This acquisition may represent a significant strategic expansion for Kaisa Health Group Holdings Limited. The terms of the agreement and the nature of Embrace Blossom Limited’s business could materially affect future earnings and share value.
- Share Issuance and Dilution: The issuance of a large number of consideration shares to the Vendor will dilute existing shareholders unless offset by increased value from the acquisition. The pricing of the shares (HK\$9.8 post-consolidation, HK\$0.196 pre-consolidation) may affect perceived value.
- Share Consolidation: The consolidation will reduce the number of shares, which generally increases the share price per unit but can affect liquidity and investor perception. Fractional entitlements will be settled by the Directors, potentially through sale for the benefit of the Company.
- Regulatory Approval: The share consolidation is contingent upon approval from the Stock Exchange Listing Committee. If not granted, the share issuance will proceed at the pre-consolidation level, affecting dilution and share price differently.
- Timing and Process: The closure of the register and proxy arrangements are important for shareholders who wish to vote or attend. Shareholders should note deadlines for share transfers and proxy submissions.
Details for Shareholders
- Shareholders entitled to attend, speak, and vote can appoint one or more proxies. Proxies need not be shareholders themselves.
- Joint holders of shares: Seniority is determined by the order of names in the register. Only the most senior present holder’s vote will count.
- Voting will be by poll, not show of hands.
- Weather protocols: If Typhoon Signal No. 8 or above, “extreme conditions,” or Black Rainstorm Warning is in effect three hours before the meeting, the SGM will be postponed and new details will be announced.
- Board composition: The Board consists of several executive and independent non-executive directors, headed by Chairman Kwok Ying Shing.
Conclusion
The proposed acquisition and share consolidation are major corporate actions. These could have material impacts on the Company’s share structure, shareholder value, and strategic direction. Investors should closely monitor the outcome of the SGM as approval or rejection of these resolutions could significantly move the share price.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions. The information is based on the official notice and may be subject to change pending shareholder approval and regulatory processes.
佳兆業健康集團控股有限公司 — 股東特別大會及關鍵企業行動詳情
重點摘要
- 特別股東大會（SGM）召開：大會定於2026年6月22日星期一上午11時，於香港上環永樂街93-103號Office Plus @Sheung Wan 20樓Luxe Lab會議室舉行。
- 重大收購議案：股東需批准佳兆業健康集團控股有限公司向Profit Vigorous Developments Limited（賣方）收購Embrace Blossom Limited全部已發行股本。
- 股份發行：公司將向賣方發行新股份作為收購對價：
- 若股份合併生效，將發行2,491,042股對價股份，每股發行價為港幣9.8元。
- 若股份合併未生效，將發行124,552,111股對價股份，每股發行價為港幣0.196元。
- 股份合併：公司建議將每五十（50）股已發行及未發行普通股（每股面值港幣0.00125元）合併為一（1）股普通股（每股面值港幣0.0625元）。此舉將大幅減少流通股份數量，或影響流動性及股價。
- 董事授權：董事將獲授權執行所有必要文件及行動，以完成收購、股份發行及合併。
- 股東投票：所有決議將以投票方式決定，股東可委任代理人出席及投票。
- 股東登記冊關閉：2026年6月16日至6月22日期間登記冊將關閉，股權轉讓需於6月15日16:30前辦理。
- 天氣安排：如遇香港8號或以上風球、政府宣布極端情況或黑色暴雨警告，大會將延期，並另行公告。
對股東可能影響股價的重點
- 收購Embrace Blossom Limited：此收購或為公司帶來重大戰略擴張，協議條款及目標公司業務或對未來盈利及股價有實質影響。
- 股份發行及稀釋：大量發行對價股份將稀釋現有股東權益，除非收購帶來相應價值提升。股份發行價格（合併後港幣9.8元，合併前港幣0.196元）或影響市場價值認知。
- 股份合併：合併後股份數目減少，單位股價上升，但或影響流動性及投資者觀感。董事將安排處理合併產生的零碎股權。
- 監管批准：股份合併須獲聯交所上市委員會批准，否則股份將按未合併情況發行，對稀釋及股價影響不同。
- 時序及流程：登記冊關閉及代理安排對欲參與投票或出席的股東尤為重要，需留意相關截止日期。
股東需知詳情
- 股東有權委任一名或多名代理人出席及投票，代理人毋須為股東。
- 聯名持股：以登記冊先登名字排序，最先者投票為準。
- 所有決議以投票方式決定。
- 天氣安排：如會議前三小時內8號或以上風球、極端情況或黑色暴雨警告生效，大會將延期並公告。
- 董事會組成：主席郭英成及多名執行、獨立非執行董事。
結論
本次收購及股份合併屬重大企業行動，可能對公司股權結構、股東價值及戰略方向產生實質影響。投資者應密切留意特別大會決議結果，相關決議的通過或否決或將明顯影響股價。
免責聲明
本文僅供參考，並非投資建議。投資者應自行進行盡職調查及諮詢專業顧問。如有任何投資決定，請自行承擔風險。以上資訊來自公司公告，或因股東批准及監管程序而有所變動。
